Butan-2-Yl [1-Methyl-4-[[4-[[4-Methyl-3-[(4-Pyridin-3-Ylpyrimidin-2-Yl)Amino]Phenyl]Carbamoyl]Phenyl]Methyl]Piperazin-1-Ium-1-Yl]Methyl Carbonate Methanesulfonate

1 trials

Filter these 1 trials by condition, phase, country and more.

1 Registered trials

0 Recruiting

0 Completed trials

1 Sponsors

13 Countries

Phase II/III

Phase II/III: 1

Sponsors using this IMP

1 total

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH). Pending

2024-520218-23-00 Phase II/III 13 countries Inhibikase Therapeutics Inc.

Showing 1–1 of 1 trials